Ciprolet drops 0.3%, 5 ml

Treatment of infectious and inflammatory diseases of the eye and its appendages caused by bacteria sensitive to the drug:

acute and subacute conjunctivitis;

blepharoconjunctivitis, blepharitis;

bacterial corneal ulcers;

bacterial keratitis and keratoconjunctivitis;

chronic dacryocystitis and meibomitis.

Preoperative prophylaxis in ophthalmic surgery.

Treatment of postoperative infectious complications. Treatment and prevention of infectious complications of the eyes after trauma or foreign bodies

Apply topically.

For mild to moderately severe infections, 1-2 drops are instilled into the conjunctival sac of the affected eye every 4 hours, for severe infections, 2 drops every hour. After improvement of the condition, the dose and frequency of instillations are reduced. With a bacterial corneal ulcer, 1 drop is prescribed every 15 minutes for 6 hours, then 1 drop every 30 minutes during waking hours; on day 2 - 1 drop every hour during waking hours; from 3 to 14 days - 1 drop every 4 hours during waking hours. If epithelialization has not occurred after 14 days of therapy, treatment can be continued.

Eye drops are colorless or light yellow, transparent.

1 ml

ciprofloxacin hydrochloride 3.49 mg,?

which corresponds to the content of ciprofloxacin 3 mg

Excipients: disodium edetate - 0.5 mg, sodium chloride - 9 mg, benzalkonium chloride 50% solution - 0.0002 ml, hydrochloric acid - 0.000034 mg, water d / i - up to 1 ml.

• viral keratitis;

• pregnancy;

• lactation period (breastfeeding);

• children's age up to 1 year;

• hypersensitivity to drug components;

• hypersensitivity to other drugs of the quinolone group.

• The drug should be used with caution in patients with cerebral atherosclerosis, cerebrovascular accident, convulsive syndrome.

pharmachologic effect

A broad-spectrum antimicrobial drug, a fluoroquinolone derivative. Suppresses bacterial DNA gyrase (topoisomerases II and IV, responsible for the process of supercoiling of chromosomal DNA around nuclear RNA, which is necessary for reading genetic information), disrupts DNA synthesis, growth and division of bacteria; causes pronounced morphological changes (including the cell wall and membranes) and rapid death of the bacterial cell. It acts bactericidal on gram-negative organisms during dormancy and division (since it affects not only DNA gyrase, but also causes lysis of the cell wall), it acts on gram-positive microorganisms only during the period of division. Low toxicity for cells of a macroorganism is explained by the absence of DNA gyrase in them.

Against the background of the use of ciprofloxacin, there is no parallel development of resistance to other antibiotics that do not belong to the group of DNA gyrase inhibitors, which makes it highly effective against bacteria that are resistant, for example, to aminoglycosides, penicillins, cephalosporins, tetracyclines and many other antibiotics.

Gram-negative aerobic bacteria are susceptible to ciprofloxacin: enterobacteria (Escherichia coli, Salmonella spp., Shigella spp., Citrobacter spp., Klebsiella spp., Enterobacter spp., Proteus mirabilis, Proteus alwards. , Morganella morganii, Vibrio spp., Yersinia spp.); other gram-negative bacteria (Haemophilus spp., Pseudomonas aeruginosa, Moraxella catarrhalis, Aeromonas spp., Pasteurella multocida, Plesiomonas shigelloides, Campylobacter jejuni, Neisseria spp.); some intracellular pathogens: Legionella pneumophila, Brucella spp., Chlamydia trachomatis, Listeria monocytogenes, Mycobacterium tuberculosis, Mycobacterium kansasii, Corynebacterium diphtheriae; gram-positive aerobic bacteria: Staphylococcus spp. (Staphylococcus aureus,Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus saprophyticus), Streptococcus spp. (Streptococcus pyogenes, Streptococcus agalactiae).

Most methicillin-resistant staphylococci are also resistant to ciprofloxacin. The sensitivity of Streptococcus pneumoniae, Enterococcus faecalis, Mycobacterium avium (located intracellularly) is moderate (high concentrations are required to suppress them).

Resistant to the drug: Bacteroides fragilis, Pseudomonas cepacia, Pseudomonas maltophilia, Ureaplasma urealyticum, Clostridium difficile, Nocardia asteroides. Not effective against Treponema pallidum.

Resistance develops extremely slowly, since, on the one hand, after the action of ciprofloxacin, there are practically no persistent microorganisms, and on the other hand, bacterial cells do not have enzymes that inactivate it.

Pharmacokinetics

Suction

After using eye drops, Cmax of ciprofloxacin in plasma is less than 5 ng / ml. Average concentration is below 2.5 ng / ml. After instillation, systemic absorption of the drug is possible.

Withdrawal

Ciprofloxacins are excreted by the kidneys mainly unchanged (50%) in the form of metabolites (up to 10%), about 15% is excreted through the intestines.

Excreted in breast milk.

Side effect

From the side of the organ of vision: itching, burning, mild soreness and hyperemia of the conjunctiva; rarely - eyelid edema, photophobia, lacrimation, a foreign body sensation in the eyes, decreased visual acuity, the appearance of a white crystalline precipitate in patients with corneal ulcers, keratitis, keratopathy, corneal infiltration.

Others: allergic reactions, nausea; rarely - an unpleasant taste in the mouth immediately after instillation, the development of superinfection.

Application during pregnancy and lactation

The use of the drug CiproletЃ is contraindicated during pregnancy and lactation (breastfeeding).

Application in children

It is contraindicated for use in children under the age of 1 year.

special instructions

Eye drops can be used only topically; the drug cannot be administered subconjunctivally or into the anterior chamber of the eye.

When using CiproletЃ eye drops and other ophthalmic solutions, the interval between their administrations should be at least 5 minutes.

It is not recommended to wear contact lenses during the period of drug treatment.

Influence on the ability to drive vehicles and use mechanisms

Patients who temporarily lose vision clarity after application are not recommended to drive a car or work with complex equipment, or with any complex equipment requiring clear vision immediately after instillation of the drug.

Overdose

There are no data on overdose of CiproletЃ when applied topically.

Symptoms: there are no specific symptoms in case of accidental ingestion of the drug. There may be nausea, vomiting, diarrhea, headache, fainting, anxiety.

Treatment: standard emergency measures, adequate fluid intake, creating an acidic urine reaction to prevent crystalluria.

Drug interactions

When combined with the drug CiproletЃ with other antimicrobial agents (beta-lactam antibiotics, aminoglycosides, clindamycin, metronidazole), synergism is usually observed. CiproletЃ can be successfully used in combination with azlocillin and ceftazidime for infections caused by Pseudomonas spp .; with mezlocillin, azlocillin and other beta-lactam antibiotics - for streptococcal infections; with isoxazolpenicillins and vancomycin - for staphylococcal infections; with metronidazole and clindamycin - for anaerobic infections.

Pharmaceutical interactions

Ciprofloxacin solution is pharmaceutically incompatible with drugs with a pH value of 3-4, which are physically or chemically unstable.